Technical Analysis for DFFN - Diffusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 1.4345 2.46% 0.03
DFFN closed down 17.65 percent on Thursday, October 17, 2019, on 6.92 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DFFN trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 2.46%
Volume Surge Other 2.46%
New 52 Week Low Weakness 2.46%
Wide Bands Range Expansion 2.46%
Below Lower BB Weakness 2.46%
Lower Bollinger Band Touch Weakness 2.46%
Oversold Stochastic Weakness 2.46%
20 DMA Resistance Bearish -15.62%
New 52 Week Closing Low Bearish -15.62%
Expansion Breakdown Bearish Swing Setup -15.62%

Older signals for DFFN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.
Medicine Biotechnology Cancer Oncology Chemotherapy Cancer Treatments Radiation Radiation Therapy Glioblastoma Macular Degeneration Brain Tumor Signal Transduction Glioblastoma Multiforme Acne Vulgaris Mtor Oncology Applications
Is DFFN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.0
52 Week Low 1.31
Average Volume 43,952
200-Day Moving Average 2.9007
50-Day Moving Average 1.9641
20-Day Moving Average 1.8603
10-Day Moving Average 1.732
Average True Range 0.146
ADX 19.65
+DI 9.6728
-DI 33.2942
Chandelier Exit (Long, 3 ATRs ) 1.762
Chandelier Exit (Short, 3 ATRs ) 1.748
Upper Bollinger Band 2.21
Lower Bollinger Band 1.5106
Percent B (%b) -0.16
BandWidth 37.596087
MACD Line -0.1113
MACD Signal Line -0.081
MACD Histogram -0.0303
Fundamentals Value
Market Cap 19.63 Million
Num Shares 14 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 0.00
Price-to-Book 15.05
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.84
Resistance 3 (R3) 1.85 1.73 1.76
Resistance 2 (R2) 1.73 1.62 1.72 1.74
Resistance 1 (R1) 1.56 1.55 1.50 1.55 1.71
Pivot Point 1.44 1.44 1.41 1.43 1.44
Support 1 (S1) 1.27 1.33 1.21 1.26 1.09
Support 2 (S2) 1.15 1.26 1.14 1.06
Support 3 (S3) 0.98 1.15 1.04
Support 4 (S4) 0.97